多西紫杉醇联合卡培他滨治疗晚期乳腺癌的疗效观察  

Clinical effect of advanced breast cancer treated by docetaxel combined with capecitabine

作　　者：田新庆 王文珍 王小娜 

机构地区：[1]临汾市肿瘤医院外科,山西临汾041000

出　　处：《现代肿瘤医学》2012年第12期2519-2521,共3页Journal of Modern Oncology

摘　　要：目的:观察多西紫杉醇联合卡培他滨方案对蒽环类耐药的晚期乳腺癌患者的临床疗效及毒副作用。方法:36例既往接受过蒽环类(其中5例接受过紫杉醇)等药物化疗的晚期乳腺癌患者,均有临床观察指标,采用多西紫杉醇联合卡培他滨化疗2-4周期,每3周重复一次,行2周期治疗后判定疗效。结果:36例中CR5例,PR 19例,NC 9例,PD 3例,总有效率为66.7%。主要不良反应为白细胞减少、脱发,其它毒副反应均较轻微可耐受,无化疗相关死亡。结论:国产多西紫杉醇联合卡培他滨治疗蒽环类耐药的晚期乳腺癌有较好疗效,不良反应轻,耐受性好,是治疗对蒽环类耐药的晚期乳腺癌较好的方案。Objective：To observe the curative effect and toxicity of semimonthly docetaxel plus capecitabine in advenced breast cancer patients who were drug resistance in using anthracene nucleus drugs.Methods： All 36 patients with advanced breast cancer who had received anthracycline chemotherapy before（5 patients had been treated with paclitaxel） were observed.These patients received docetaxel combined with capectabine for 2-4 cycles.Three weeks as one cycle.Efficacy was evaluated after 2 cycles.Results： Of these 36 patients,5 patients got complete remission,19 patients partial remission,9 pationts stable disease,and 3 patients progression.The overall response rate was 66.7%.The main toxicities were alopecia,neutropenia,and other side effects were mild.There was no any death during treatment.Conclusion： Combintion chemotherapy of semimonthly docetaxel and capecitabine has a good anti-tumor effect and tolerable toxicity on advanced breast cancer patients who were drug resistant in using anthracene nucleus drugs.

关 键 词：多西紫杉醇 卡培他滨 蒽环类耐药 晚期乳腺癌 

分 类 号：R737.9[医药卫生—肿瘤]